search
Back to results

Bi-Level Positive Airway Ventilation for Acute Chest Syndrome

Primary Purpose

Sickle Cell Anemia, Acute Chest Syndrome

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Bi-level positive airway pressure device
Sham CPAP
Sponsored by
Albert Einstein College of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Sickle Cell Anemia

Eligibility Criteria

4 Years - 21 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • patients diagnosed with Hemoglobin SS (HB SS), the most common type of sickle cell disease
  • patients diagnosed with Hemoglobin SC (HB SC), the second most common type of sickle cell disease.
  • patients diagnosed with Hemoglobin sickle beta-zero thalassemia ( HB SB0thal) or Hemoglobin sickle thalassemia (HB SBthal)

Must meet clinical criteria for ACS- an infiltrate on Chest X-ray and one of the following:

  • Respiratory symptoms/signs (patients pulse oximetry < 92% or oxygen saturation < 2% below their baseline, tachypnea, cough, and increased work of breathing)
  • Fever
  • Chest pain AND

Patients' eligible for a simple transfusion based on one of the following criteria:

  • Hypoxemia (patients pulse oximetry < 92% or oxygen saturation < 2% below their baseline)
  • Hemoglobin < 5 gm/dl
  • Increased work of breathing

Exclusion Criteria:

  • Patient requires exchange transfusion within first 24 hours of admission
  • Patient requires PCCU transfer within first 24 hours of admission
  • Hemoglobin > 9gm/dl secondary to these patients requiring an exchange transfusion

Sites / Locations

  • Children's Hospital @ Montefiore

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Bi-level Positive Airway Pressure Device

Sham CPAP

Arm Description

BiPAP initiated for at least 16 hours per day for a minimum of 48hrs.

Physiologic continuous positive airway pressure (CPAP) initiated for at least 16 hours per day for a minimum of 48hrs.

Outcomes

Primary Outcome Measures

Length of Stay as Measured by the Time From Initial Diagnosis of ACS Until Meeting Discharge Criteria.
Length of stay as measured by the time from initial diagnosis of ACS until meeting discharge criteria. It is anticipated length of stay will correlate to efficacy of treatment: shorter stay is theorized to indicate more efficient treatment.

Secondary Outcome Measures

Rate of Exchange Transfusions.
Determine Parent and Patient Acceptability of BLPAP Administration in the Setting of ACS.
Rate of PCCU Transfers.
Difference in Respiratory Rate.
Difference in Pulmonary Function Tests.
Difference in Mean SpO2 Recording During Sleep.
Peripheral capillary oxygen saturation (SpO2) is an estimate of the amount of oxygen in the blood. It is the percentage of haemoglobin containing oxygen compared to the total amount of haemoglobin in the blood (i.e. oxygenated haemoglobin vs oxygenated and non-oxygenated haemoglobin).

Full Information

First Posted
April 30, 2012
Last Updated
November 19, 2018
Sponsor
Albert Einstein College of Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT01589926
Brief Title
Bi-Level Positive Airway Ventilation for Acute Chest Syndrome
Official Title
Early Bi-Level Positive Airway Pressure (BiPAP) Ventilation for Acute Chest Syndrome (ACS) - a Double-Blind Randomized Controlled Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
November 2018
Overall Recruitment Status
Terminated
Why Stopped
Low enrollment
Study Start Date
July 2012 (Actual)
Primary Completion Date
September 8, 2016 (Actual)
Study Completion Date
September 8, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Albert Einstein College of Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Acute chest syndrome (ACS) is a frequent complication of sickle cell disease and is diagnosed by having findings on a chest x-ray and one of the following: chest pain, fever, or trouble breathing. Patients with Acute Chest Syndrome can get very sick and require an exchange transfusion (special large blood transfusion) and mechanical ventilation. Bi-level Positive Airway Pressure (also known as BLPAP or BiPAP) is a device that blows air into a patients lungs via a mask that covers the nose. The goal of this study is to determine whether giving children BiPAP when they have ACS, in addition to providing standard clinical care for ACS, alters the clinical course of these patients. The investigators hypothesize that patients receiving effective BiPAP will have milder clinical courses resulting in shorter hospital stays and fewer transfers to the intensive care unit and exchange transfusions.
Detailed Description
Acute chest syndrome (ACS) is a frequent complication of sickle cell disease and is diagnosed by a new infiltrate on chest x-ray and one of the following: chest pain, fever, or respiratory signs or symptoms (tachypnea, cough, new onset hypoxemia, or increased work of breathing.)The treatment for acute chest syndrome is focused on supportive care with hydration, antibiotics, blood transfusions and respiratory support. Unfortunately, despite these treatments many patients fail to have improvements in their respiratory status, or have respiratory decompensation. These patients require more aggressive treatments, which frequently include exchange transfusions, pediatric intensive care unit (PCCU) management, and respiratory support. The study objective is to perform a prospective double blind randomized control trial to investigate if early initiation of effective BiPAP in addition to providing standard clinical care for ACS alters the clinical course of these patients vs. sham BiPAP and standard clinical care. Investigators hypothesize that participants receiving effective BiPAP will have milder clinical courses resulting in shorter hospital stays and fewer transfers to PCCU and exchange transfusions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sickle Cell Anemia, Acute Chest Syndrome

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
3 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Bi-level Positive Airway Pressure Device
Arm Type
Experimental
Arm Description
BiPAP initiated for at least 16 hours per day for a minimum of 48hrs.
Arm Title
Sham CPAP
Arm Type
Sham Comparator
Arm Description
Physiologic continuous positive airway pressure (CPAP) initiated for at least 16 hours per day for a minimum of 48hrs.
Intervention Type
Device
Intervention Name(s)
Bi-level positive airway pressure device
Intervention Description
BiPAP initiated for at least 16 hours per day for a minimum of 48hrs.
Intervention Type
Device
Intervention Name(s)
Sham CPAP
Intervention Description
Sham CPAP initiated for at least 16 hours per day for a minimum of 48hrs.
Primary Outcome Measure Information:
Title
Length of Stay as Measured by the Time From Initial Diagnosis of ACS Until Meeting Discharge Criteria.
Description
Length of stay as measured by the time from initial diagnosis of ACS until meeting discharge criteria. It is anticipated length of stay will correlate to efficacy of treatment: shorter stay is theorized to indicate more efficient treatment.
Time Frame
From diagnosis of ACS until meeting discharge criteria- Average 7 days.
Secondary Outcome Measure Information:
Title
Rate of Exchange Transfusions.
Time Frame
Diagnosis until discharge. Average 7 days.
Title
Determine Parent and Patient Acceptability of BLPAP Administration in the Setting of ACS.
Time Frame
Upon completion of intervention at 48hrs.
Title
Rate of PCCU Transfers.
Time Frame
Diagnosis until discharge. Average 7 days.
Title
Difference in Respiratory Rate.
Time Frame
48hrs after initiation of treatment
Title
Difference in Pulmonary Function Tests.
Time Frame
48hrs after initiation of treatment
Title
Difference in Mean SpO2 Recording During Sleep.
Description
Peripheral capillary oxygen saturation (SpO2) is an estimate of the amount of oxygen in the blood. It is the percentage of haemoglobin containing oxygen compared to the total amount of haemoglobin in the blood (i.e. oxygenated haemoglobin vs oxygenated and non-oxygenated haemoglobin).
Time Frame
48hrs after initiation of treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
4 Years
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patients diagnosed with Hemoglobin SS (HB SS), the most common type of sickle cell disease patients diagnosed with Hemoglobin SC (HB SC), the second most common type of sickle cell disease. patients diagnosed with Hemoglobin sickle beta-zero thalassemia ( HB SB0thal) or Hemoglobin sickle thalassemia (HB SBthal) Must meet clinical criteria for ACS- an infiltrate on Chest X-ray and one of the following: Respiratory symptoms/signs (patients pulse oximetry < 92% or oxygen saturation < 2% below their baseline, tachypnea, cough, and increased work of breathing) Fever Chest pain AND Patients' eligible for a simple transfusion based on one of the following criteria: Hypoxemia (patients pulse oximetry < 92% or oxygen saturation < 2% below their baseline) Hemoglobin < 5 gm/dl Increased work of breathing Exclusion Criteria: Patient requires exchange transfusion within first 24 hours of admission Patient requires PCCU transfer within first 24 hours of admission Hemoglobin > 9gm/dl secondary to these patients requiring an exchange transfusion
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Deepa Manwani, MD
Organizational Affiliation
Albert Einstein College of Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Michael E Roth, MD
Organizational Affiliation
Albert Einstein College of Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kerry Morrone, MD
Organizational Affiliation
Albert Einstein College of Medicine
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Hiren Muzumdar, MD
Organizational Affiliation
Albert Einstein College of Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ranaan Arens, MD
Organizational Affiliation
Albert Einstein College of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's Hospital @ Montefiore
City
Bronx
State/Province
New York
ZIP/Postal Code
10467
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Bi-Level Positive Airway Ventilation for Acute Chest Syndrome

We'll reach out to this number within 24 hrs